Chargement en cours...
Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to derisk clinical trials
BACKGROUND: Patients with type 2 myocardial infarction (T2MI) and other mechanisms of nonthrombotic myocardial injury have an unmet therapeutic need. Eligibility for novel medical therapy is generally uncertain. METHODS: We predefined colchicine, eplerenone and ticagrelor as candidates for repurposi...
Enregistré dans:
| Publié dans: | Open Heart |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Publishing Group
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8174491/ https://ncbi.nlm.nih.gov/pubmed/34083388 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/openhrt-2021-001633 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|